With around 2 million Americans living with type 1 diabetes and an increasing number of insulin-requiring type 2 cases, the US healthcare system is experiencing growing demand for simplified, automated diabetes care. The integration of Abbott Laboratories’ FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with the Tandem t:slim X2 insulin pump system marks a significant evolution in diabetes technology. This development comes aligned with the growing adoption of automated insulin delivery (AID) systems, says GlobalData.
From a regulatory and clinical care standpoint, this shift is consistent with the updated guidance from the American Diabetes Association, which now endorses automated insulin delivery (AID) systems as the leading approach for individuals with type 1 diabetes and others requiring intensive insulin therapy.
Additionally, the recent FDA clearance of these systems for use in type 2 diabetes reflects a broader acknowledgement of their effectiveness across diverse patient populations, signalling increased confidence in their real-world utility and potential for wider adoption.
Elia Garcia, Medical Analyst, GlobalData, comments, “We are seeing a transition from standalone devices to fully integrated platforms designed around data flow, personalisation, and patient usability. Patients are also more inclined to support systems that deliver measurable outcomes and reduce long-term complications.”
Integrated systems that automate insulin delivery based on continuous glucose data have shown not only better glycemic control but also a reduction in cognitive and emotional burden on users. As these technologies evolve, the emphasis is shifting from short-term metrics to long-term sustainability, prioritising ease of use, minimal disruption to daily life, and adaptability across age groups and clinical profiles.
Garcia concludes, “As adoption expands, the market is rewarding technologies that combine extended sensor performance, updatable algorithms, and broader patient indications. The result is an increasingly scalable model of diabetes care centred not just on blood glucose management, but on user autonomy, long-term adherence, and systemic efficiency.”
